Skip to content

Basic and clinical innovative research on vesicourethral dysfunction and its multidimensional regulation - Building a predictive model based on machine learning algorithm to evaluate the efficacy of one-stage sacral neuroregulation in the treatment of neurogenic bladder

Basic and clinical innovative research on vesicourethral dysfunction and its multidimensional regulation - Building a predictive model based on machine learning algorithm to evaluate the efficacy of one-stage sacral neuroregulation in the treatment of neurogenic bladder

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400083598
Enrollment
Unknown
Registered
2024-04-29
Start date
2024-05-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurogenic bladder

Interventions

model training set group:None
model test set group:None

Sponsors

Beijing Boai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Patients aged 18-75 years with neurogenic bladder (including boundary values), regardless of gender; (2) Voluntarily sign a written informed consent; (3) Able to communicate well with the investigator and willing to comply with the requirements of the entire experiment

Exclusion criteria

Exclusion criteria: (1) Patients with low bladder compliance (less than 20ml/cmH2O) during urodynamic examination; (2) Patients with mechanical obstruction of outflow tract; (3) Patients with complete spinal cord injury; (4) symptomatic urinary infection; (5) Patients with hydronephrosis or vesico-ureter reflux; (6) Patients with renal insufficiency (blood creatinine greater than 1.5 times the upper limit of normal); (7) Bladder and prostate cancer patients; (8) Patients with implanted pacemakers or defibrillators; (9) Senile dementia, brain atrophy, acute phase of cerebrovascular disease, cognitive impairment (10) Epilepsy, mental disorders can not cooperate with the doctor; (11) Patients who are positive for infectious disease screening before surgery (hepatitis B surface antigen, hepatitis C antibody, syphilis antibody and HIV antibody); (12) Pregnant women or patients trying to become pregnant; (13) Participants who participated in other clinical trials 3 months before the trial; (14) Other situations in which the researcher considers it inappropriate to participate in the study.

Design outcomes

Primary

MeasureTime frame
Change in urination frequency from baseline;Frequency of urgent urination;American Urological Association Symptom Index,AUA-SI;Residual urine volume change;Maximum urine flow rate;

Secondary

MeasureTime frame
Nocturia frequency;Frequency of urinary incontinence;Volume of urine per discharge;Patient Perception of Bladder Condition- Scale, PPBC-S;quality of life;neurogenic bowel dysfunction;Intermittent catheterization times;Proportion of patients completely disengaged from intermittent catheterization;The incidence of adverse events;

Countries

China

Contacts

Public ContactLiao Limin

China Rehabilitation Research Center,Beijing Boai Hospital

lmliao@263.net+86 87569043

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026